Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Elanco: Acquisition of Bayer's animal health business seen closing mid year » 06:34
03/24/20
03/24
06:34
03/24/20
06:34
ELAN

Elanco

$16.95 /

-0.58 (-3.31%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

Elanco's (ELAN)…

Elanco's (ELAN) excitement related to the addition of Bayer's (BAYRY) animal health business is unabated by the COVID-19 situation as it confirms the value of diversifying our companion animal business into the over-the-counter market. Likewise, the expanded global scale puts Elanco in a stronger position to weather tough business environments over the long-term as the combined company focuses on innovating to meet unmet needs of animals for veterinarians, farmers and pet owners across the globe. The pending acquisition continues to advance toward a mid-year 2020 closing. Elanco has received regulatory clearance in China, Colombia, Turkey and the Ukraine, and is continuing to collaborate with other key jurisdictions. Elanco has signed agreements to divest certain products it anticipates will be necessary to complete these reviews. Further, Elanco has fully secured financing to complete the transaction through its completed equity issuance and pricing of its Term Loan B earlier in the first quarter. Given the recent decline in interest rates, Elanco entered into derivative transactions to swap a portion of its floating interest rate on the $4.275B Term Loan B to a fixed rate obligation. These derivative transactions provide greater certainty on the Term Loan B interest expense. Elanco's first significant obligation after completing the acquisition is its $500M in senior notes due August 27, 2021. Both Bayer and Elanco continue to collaborate virtually, making significant progress toward Day 1 readiness, integration planning and value capture.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Elanco withdraws FY20 guidance due to COVID-19 impact » 06:32
03/24/20
03/24
06:32
03/24/20
06:32
ELAN

Elanco

$16.95 /

-0.58 (-3.31%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

As Elanco Animal Health…

As Elanco Animal Health (ELAN) evaluates the potential impact of the COVID-19 pandemic, it is providing an update on its business and financial position, as well as the actions it is taking to support employees, customers and public health. "In this time of uncertainty, the health and well-being of our employees, customers, animals and the communities where we operate are our top priority," said Jeff Simmons, Elanco president and CEO. "Our team is actively undertaking precautionary measures to keep our employees safe, while continuing to provide our customers with the products they need. Such an unprecedented time underscores the critical importance of a safe, affordable food supply, particularly meat, milk and eggs, and the role of healthy pets, bringing much needed companionship to families everywhere." Simmons continued, "I remain confident in Elanco's long-term strategy and our ability to deliver on the commitments to our stakeholders. The underlying industry fundamentals remain strong and the diversity of the global Elanco business across farm animals and pets provides durability and balance. We are resolute in our acquisition of Bayer AG's (BAYRY) animal health business as it adds to our leadership position in animal health for the long-term." As the situation around the COVID-19 pandemic is rapidly evolving, Elanco is withdrawing its previously announced 2020 revenue and earnings per share guidance. Elanco is monitoring several global dynamics, from changing foreign currency rates and a dynamic animal protein market to declining veterinary clinic visits, the growing use of direct-to-consumer shipping, and sales through ecommerce and other alternative channels. The company is confident in its working capital and liquidity levels, while continuing to actively monitor the changing environment across the world. Elanco will provide an update on its Q1 earnings call in early May, based on information available at that time. The Elanco team remains focused and in execution mode, even as much of the employee base moves to remote working. The manufacturing plants and R&D labs are operational, and the company is closely monitoring distribution logistics. At this time, Elanco has not experienced any supply disruption and critical projects in the pipeline continue to advance. The U.S. Department of Homeland Security and most other countries globally have deemed manufacturing and distribution of animal medicines as essential critical infrastructure and workforce. However, in an effort to support public health and slow the spread of the disease, Elanco moved its non-business critical work force to remote working globally, with the exception of China, which has begun to return to work. Elanco also removed sales representatives from the field in many countries, including the U.S. along with its companion animal distribution partners. However, the Elanco team continues to collaborate with customers via webinars, teleconference and video conferences and other remote options. Much like the human health system, the American Veterinary Medical Association, along with industry organizations across Europe and other countries, has recommended limiting patient care to acutely ill animals and emergencies, rescheduling annual exams and elective procedures. This guidance increases the importance of telemedicine, direct shipment and alternative channels, while underscoring the significance and value of Elanco's pending acquisition of Bayer AG's animal health business.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Hot Stocks
Elanco Animal Health trading resumes  10:09
03/12/20
03/12
10:09
03/12/20
10:09
ELAN

Elanco

$23.73 /

+ (+0.00%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Elanco Animal Health trading halted, volatility trading pause  10:04
03/12/20
03/12
10:04
03/12/20
10:04
ELAN

Elanco

$23.73 /

+ (+0.00%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Conference/Events
BofA/Merrill to hold a summit » 07:51
02/24/20
02/24
07:51
02/24/20
07:51
ELAN

Elanco

$31.16 /

+0.935 (+3.09%)

, IDXX

Idexx Laboratories

$278.55 /

-2.92 (-1.04%)

, KIN

Kindred Biosciences

$10.25 /

+0.85 (+9.04%)

, PETZ

TDH Holdings

$1.46 /

-0.1 (-6.41%)

, ZTS

Zoetis

$142.14 /

-1.39 (-0.97%)

Animal Health Summit to…

Animal Health Summit to be held in New York on February 24.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Elan to divest worlwide rights for Vecoxan for $55M in all cash deal » 16:40
02/19/20
02/19
16:40
02/19/20
16:40
ELAN

Elanco

$29.94 /

-0.55 (-1.80%)

, MRK

Merck

$82.00 /

-0.46 (-0.56%)

Elanco Animal Health…

Elanco Animal Health Incorporated (ELAN) annouonced it signed an agreement with Merck Animal Health (MRK) to divest worldwide rights for Vecoxan for $55 million in an all-cash deal. Vecoxan is used for prevention and treatment of coccidiosis in calves and lambs. Divesting the rights to Vecoxan brings divestitures to-date into the $120 million to $140 million revenue range Elanco previously stated it expected across both companies. In total, these divestitures have generated approximately $425 million in pre-tax proceeds, which will be used to pay down debt associated with the transaction. The closing of the transaction with Vecoxan is contingent on Elanco closing its transaction with Bayer, as well as other customary closing conditions. Elanco is in advanced discussions with the required regulatory authorities, which are progressing as expected. Elanco already received antitrust clearance for the transaction in China, Turkey and Ukraine. Any proposed remedy and final clearance for the Elanco/Bayer transaction remains subject to review and approval from other regulatory authorities.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Elanco backs FY20 adjusted EPS view $1.09-$1.16, consensus $1.14 » 06:31
02/19/20
02/19
06:31
02/19/20
06:31
ELAN

Elanco

$30.49 /

-0.5 (-1.61%)

Backs FY20 revenue view…

Backs FY20 revenue view $3.05B-$3.11B, consensus $3.1B. Backs FY20 core revenue view $3B-$3.06B.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Elanco reports Q4 adjusted EPS 23c, consensus 23c » 06:29
02/19/20
02/19
06:29
02/19/20
06:29
ELAN

Elanco

$30.49 /

-0.5 (-1.61%)

Reports Q4 revenue $787M,…

Reports Q4 revenue $787M, consensus $791.5M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Notable companies reporting before tomorrow's open » 20:25
02/18/20
02/18
20:25
02/18/20
20:25
ADI

Analog Devices

$118.50 /

+0.91 (+0.77%)

, DISH

Dish

$41.25 /

+1.29 (+3.23%)

, GPC

Genuine Parts

$96.71 /

+0.235 (+0.24%)

, ELAN

Elanco

$30.49 /

-0.5 (-1.61%)

, OC

Owens Corning

$62.99 /

-0.82 (-1.29%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Analog Devices (ADI), consensus $1... Dish (DISH), consensus 59c... Genuine Parts (GPC), consensus $1.30... Elanco Animal Health (ELAN), consensus 23c... Owens Corning (OC), consensus $1.13.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Notable companies reporting before tomorrow's open » 14:52
02/18/20
02/18
14:52
02/18/20
14:52
ADI

Analog Devices

$118.20 /

+0.61 (+0.52%)

, DISH

Dish

$41.11 /

+1.15 (+2.88%)

, GPC

Genuine Parts

$96.79 /

+0.32 (+0.33%)

, ELAN

Elanco

$30.54 /

-0.45 (-1.45%)

, OC

Owens Corning

$63.10 /

-0.71 (-1.11%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Analog Devices (ADI), consensus $1... Dish (DISH), consensus 59c... Genuine Parts (GPC), consensus $1.30... Elanco Animal Health (ELAN), consensus 23c... Owens Corning (OC), consensus $1.13.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.